## **AmerisourceBergen**

MWI Animal Health®

# Retail pharmacy questionnaire

phone 800.896.8873 fax 855.854.3922 MWImaint@mwiah.com PO Box 5717, Boise, ID 83705

Form will not be processed unless all questions are completed				
MV	WI associate details:			
Na	ıme:	Phone number:		
Sei	ervicing distribution center(s) (DCs):			
	his questionnaire is to be completed by the owner or Pharmacis dditional space, please utilize the comments $/$ observations see	st in charge (PIC) of the retail pharmacy and MWI associate. If you require ction.		
Se	ection I – General information			
1.	Pharmacy name (as it appears on the DEA registration):			
	DBA:			
2.	Pharmacy address (as it appears on the DEA registration):			
	Street:	City:		
	State: Zip:	Phone:		
	Email:	Website:		
<ol> <li>Select the following reason for controlled substancemonitoring program (CSMP) review:</li> </ol>		ng program (CSMP) review:		
	Start-up business			
	Established business <b>changing</b> supplier(s) to MWI or <b>add</b>	ling MWI as supplier(s)		
	Change in ownership – indicate existing account number	er:		
	Is a Power of Attorney from the prior owner being utilized	d? Yes No lf yes, provide a copy		
	Updated CSMP 590 form – indicate account number: _			
	Reason for updated form:			
	Reinstatement to purchase controlled substance and/o	r listed chemical products:		
4.	Select if you have a current account with AB or any other sub:	sidiary subsidiary and indicate applicable account number:		
	Besse Medical:	Oncology Supply:		
	AmerisourceBergen:	ASD:		
	☐ ICS:	Smartsource:		

#### Section II – Pharmacy business model

5.	hat percentage of the following describes the pharmacy's business activity? Selection(s) should add up to 100%		
	Retail% Compounding% Closed door% Digital/Internet%		
	Mail order% Specialty% Central fill%		
6.	Is the pharmacy located within a clinic?  Yes No		
	If yes, what type of clinic?		
	Provide name of clinic:		
7.	Does the pharmacy fill controlled substance prescriptions coming from this facility / clinic? Yes No		
	If yes, are there any financial interests with the clinic(s)? Yes No		
8.	Does the pharmacy provide controlled substances to other pharmacies, practitioners, or other DEA registrants?		
9.	Does the pharmacy accept walk-in patients? Yes No		
Se	ction III – Licenses		
	Pharmacy DEA registration number: DEA business activity:		
11.	State board of pharmacy number: Controlled substance state license (if applicable):		
	Other licenses:		
13.	Is the pharmacy licensed in any other state(s)? Yes No If yes, provide state and license number below.		
Si	tate State license number		
Se	ctio IV — Pharmacy personnel and ownership		
_			
14.	Pharmacist-in-charge (PIC) name: License number:		
15.	Has the PIC been licensed in any other state in the past five (5) years?  Yes  No		
	If yes, please provide state and license number:		
16.	Pharmacy manager name (if different than PIC): License number (if applicable):		
17.	Corporate entity (if applicable):		

#### Section IV – Pharmacy personnel and ownership (cont.)

18. Please provide ownership information below:			
Owner name	State of residence	Number of years owner has operated pharmacy	Percentage of ownership
			_
19. Are any of the owners a licensed pharmacist? Yes	No 🗌		
If yes, please list license number(s) and state(s):			
20. Are any of the owners a prescribing practitioner at this pho	armacy? Yes	No 🗌	
If yes, please list license number(s) and state(s):			
21. Are any of the owners associated with or own other pharm	acies? Yes	No 🗌	
If yes, please list pharmacy name and DEA registration nur	mber:		
22. Is the owner a licensed practitioner? Yes No			
If yes, list federal /state license numbers:			
Pharmacy name	DEA	registration number	
Section V – Sanctions / discipline			
23. Has a supplier suspended, reduced, or ceased controlled s	substance sales 1	o the pharmacy or other owned pha	armacies within the last
five (5) years? Yes No If yes, please provide	details (when, wl	ny, etc.)	
24. Is this pharmacy or other owned pharmacies currently part	of an active inve	estigation at the federal, state or lo	cal level? Yes No
If yes, please provide details (when, why, etc.)			
25. Has the pharmacy or other owned pharmacies had a DEA r	registration or st	ate license / registration suspended	I, revoked or disciplined within
the last five (5) years? Yes No If yes, please p	provide details (v	vhen, why, etc.)	

#### Section V – Sanctions / discipline (cont.)

(misdemeanor or felony offer		ned pharmacies had any administrative enforcement entity (state, local, federa	
	nployee of the pharmacy or other ow plined within the last five (5) years?	ned pharmacies had a DEA registration Yes	or state license / registration ide details (when, why, etc.)
Section VI – Supplier information	on		
	narmacy's business will be serviced from	om MWI?	
29. List your controlled substand	Supplier type (primary / secondary)	Will you continue to purchase from this supplier?  (Yes / No)	What percentage of pharmacy business will be serviced from this supplier?
30. List your <b>non-controlled leg</b> o	end drug product suppliers in the tab	ole below.	
Current supplier	Supplier type (primary / secondary)	Will you continue to purchase from this supplier? (Yes / No)	What percentage of pharmacy business will be serviced from this supplier?
31. For start-ups only:  Do you intend to purchase c  If yes, list other anticipated s		emical products from any other supplier	? Yes No
Do you intend to purchase n	on-controlled legend drug products suppliers:	from any other supplier? Yes No	

#### Section VII – Prescriptions / controlled substance usage

<u> </u>						
32. How many prescriptions are filled mo	nthly?	Start-up entities please provide estimo	ites.			
33. Does the pharmacy utilize the state F	Does the pharmacy utilize the state Rx monitoring program as part of dispensing process?  Yes  No					
If no, explain in comments/observation	ons section					
34. Does this pharmacy have written pol	icies / procedures for dispensir	ng controlled substances? Yes No				
if no, explain in comments/observation	ons section					
35. Does the pharmacy fill controlled sub	ostance and/or Gabapentin pre	escriptions for out-of-state patients? Ye	es No			
		ostance / Gabapentin prescriptions and list o	applicable states:			
36. What is your ratio of in-state vs out-o	of-state patients?					
In-state patient ratio	% (	Out-of-state patient ratio	%			
37. What is the percentage of the following	ing types of products (based or	n dosage units) you expect to purchase from	AB?			
Selection(s) should add up to 100%						
Non-controlled Rx	% of total purchases	Controlled substances	% of total purchases			
		ted chemicals%	of total purchases			
38. Anticipated or actual usage of the fo	llowing controlled substances f	from all suppliers. Start-up entities please pr	ovide estimates:			
Item	Monthly usage values in dosage units	Item	Monthly usage values in dosage units			
Alprazolam	J	Methadone	J			
Amphetamine solids		Morphine	-			
Buprenorphine (single component)		Oxycodone products				
Buprenorphine (naloxone)		Oxycodone 30 mg IR				
Carisoprodol		Oxymorphone				
Fentanyl		Promethazine w/ codeine (ml)				
Hydrocodone products		Tramadol				
Hydromorphone						
39. Provide the anticipated or actual uso	ige of the top five (5) purchased	d controlled substance or listed chemical pro	oducts <b>not listed above</b> .			
Start-up entities please provide estin	nates:					
Rank Controlled substance produ	ct (name / strength / dosage	form) Monthly usage values in dosage units	Average dosage units per prescription			
1			por precempater.			
2						
3						
4						
5						

### Section VIII – Controlled substance dispensing $/\ procedure$

40. For controlled substance prescriptions, does the pharmacy:
Validate the practitioner's DEA registration via the DEA website? Yes No
Validate the practitioner's state license(s) via the State board of medicine or other authority website?
Contact the practitioner to validate a controlled substance prescription when there are questions or concerns? Yes No
Check the patient / customer photo ID? Yes No
Query the state prescription drug monitoring program (PDMP) before dispensing?
Have written policies and procedures for identifying and handling questionable or suspicious prescriptions?
Provide training and/or copies of policies and procedure to pharmacy personnel? Yes No
If no to any above questions, provide explanation in comments/observations section
Section IX — Controlled substance security
41. Does the pharmacy conduct criminal background checks on employees with access to controlled substances? [21CFR1301.76(a)]
Yes No If no, explain in the comments/observations section
Has any employee with access to controlled substances had a felony conviction related to controlled substances? Yes 🔲 No 🗌
If yes, has the pharmacy obtained the necessary waiver from the DEA? Yes 🔲 No 🗌
Has any employee with access to controlled substances had a DEA registration revoked, denied, of surrendered? Yes 🔲 No 🗌
If yes, has the pharmacy obtained the necessary waiver from the DEA? Yes 🔲 No 🗌
42. How often are background checks conducted? (e.g. prior to hiring, annually)
43. Does the pharmacy have any of the following security measures? Check all that apply.
☐ Alarm system ☐ Security camera(s) ☐ Dedicated CII storage ☐ Security guards ☐ Panic button
44. Has the pharmacy experienced any theft or loss during the past twelve (12) months? Yes 🗌 No 🔲 If yes, how many?
If yes, were they reported to the: DEA? Yes No Local law enforcement? Yes No
If yes, were any employees involved in thefts? Yes 🗌 No 🗌
Section X — Prescriber information
45. List your top five (5) prescribing practitioners of controlled substances based on dosage units (not applicable to start-up entities):
Name Specialty DEA registration Substances prescriptions
Name Specialty DEA registration substances prescriptions (per month)

#### Section X – Prescriber information (cont.)

46. Are you aware of any disciplinary and/or law enforcement action taken within the past five (5) years against any of the above practitioners,
or any prescriber you fill constrolled substance prescriptions for?
Yes No If yes, please explain (who, when, etc.)
47. Are any of the above prescribers located more than 50 miles from the pharmacy? Yes No
If yes, please explain the reason for the distance
Section XI – Payments and photos
48. Types of payments the pharmacy receives for prescriptions. Selection(s) should add up to 100%
Private insurance % Cash / credit card (excluding copays) %
Other
49. What percentage of controlled substance prescriptions are paid in cash / credit cards? (excluding copays) %
50. Attach and date photos of pharmacy. At least two (2) photos of pharmacy interior, including counter area and front end, and one (1) photo
of <b>entire exterior front of pharmacy</b> . Include additional photos that would demonstrate special services provided by the pharmacy (i.e.
sterile compounding area).

#### Section XII – Additional comments and observations

51. Please share details below:

#### Section XIII - Acknowledgment

By signing below, pharmacy acknowledges that:

MWI relies on the information provided on this form to help determine whether it will distribute controlled substances to pharmacy. Pharmacy agrees to inform MWI of any changes to its business that would impact the accuracy or completeness of the information contained herein.

MWI reserves the right, within its sole discretion, to refuse to ship controlled substances to any customer. Any materially incorrect information on the CSMP Form 590 will be grounds for MWI, at its sole discretion, to immediately cease distribution of any or all controlled substances to pharmacy and/or to terminate MWI's relationship with pharmacy. Pharmacy has an effective compliance program and adheres to all requirements imposed upon it for the distribution of controlled substances as promulgated in the CFR and by any applicable federal, state or local board of pharmacy or other regulatory body.

Pharmacy acknowledges that MWI may need to review Pharmacy's dispensing data as part of MWI's controlled substance monitoring responsibilities, including new customer onboarding, due diligence reviews, and consumption reviews. Pharmacy acknowledges that failure to provide requested dispensing data within a reasonable amount of time of the data being requested by MWI may result in Pharmacy being unable to order controlled substances from MWI. Collection and utilization of dispensing data will be compliant with applicable federal and state privacy laws, including the Health Insurance Portability and Accountability Act (HIPAA). MWI utilizes a third-party contractor to collect this data. Pharmacy acknowledges that it will need to sign a business associate agreement with MWI's third-party contractor to facilitate the data transfer.

Pharmacy will indemnify and hold harmless MWI, its parent companies, affiliates, subsidiaries, shareholders, officers, directors, employees, agents and representatives from any and all economic damage that results from pharmacy providing MWI with materially incorrect information on this form or from failing to have in place an effective compliance program.

Important note: Both MWI representative and pharmacy owner or Pharmacist in Charge (PIC) signatures must be present to initiate CSMP review.